TSC22D3 and Hepatic fibrosis: In addition to the previously mentioned GILZ and SPHK1 that play a role in regulating CCL2 expression and thereby affecting liver fibrosis progression (54, 55), several pharmacological agents can also mitigate liver fibrosis by targeting the CCL2/CCR2 signaling pathway.